GRAFT-VERSUS-HOST DISEASE (GVHD)
Clinical trials for GRAFT-VERSUS-HOST DISEASE (GVHD) explained in plain language.
Never miss a new study
Get alerted when new GRAFT-VERSUS-HOST DISEASE (GVHD) trials appear
Sign up with your email to follow new studies for GRAFT-VERSUS-HOST DISEASE (GVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lower-Dose drug may make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 41 adults and give the…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a lower drug dose improve life after stem cell transplant for older adults?
Disease control Recruiting nowThis study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard high dose of a drug (cyclophosphamide) with a lower dose, both combined with another drug (sirolimus), to prevent graft-versus-host disease (GVHD). The goal is to…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC